Efficacy and tolerability of amifostine in elderly cancer patients

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 1, 2004, Pages 113-124

  Barutca, Sabri ^a   Meydan, Nezih ^a   Akar, Harun ^a   Yavasoglu, Irfan ^a   Kadikoylu, Gurhan ^a   Bolaman, Zahit ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

adverse effects; amifostine; cisplatin; elderly cancer patients; nephrotoxicity; tolerability

Indexed keywords

AMIFOSTINE; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE MONITORING; BLOOD TOXICITY; CANCER; CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAPHORESIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; ELECTROLYTE BLOOD LEVEL; FEMALE; HEMATURIA; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; KIDNEY FUNCTION TEST; MALE; MORBIDITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TOXICITY; URINALYSIS; VOMITING;

EID: 3242709474     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)90011-2     Document Type: Article

References (30)

1. Sriswasdi C., Jootar S., Giles F.J. Amifostine and hematologic effects. J Med Assoc Thai. 83:2000;374-382
2. Genvresse I., Lange C., Schanz J., et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: A comparative study. Anticancer Drugs. 12:2001;345-349
3. Mabro M., Faivre S., Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf. 21:1999;367-387
4. Antonadou D., Coliarakis N., Synodinou M. Clinical Radiation Oncology Hellenic Group. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. published correction appears in Int J Radiat Oncol Biol Phys. 52:2002;1458
5. Antonadou D., Coliarakis N., Synodinou M. Clinical Radiation Oncology Hellenic Group. Int J Radiat Oncol Biol Phys. 54:2002;308
6. Antonadou D., Coliarakis N., Synodinou M. Clinical Radiation Oncology Hellenic Group. Int J Radiat Oncol Biol Phys. 51:2001;915-922
7. Buntzel J., Kuttnerz K., Frohlich D., Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509
8. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. published correction appears in J Clin Oncol. 18:2000;4110-4111
9. Brizel D.M., Wasserman T.H., Henke M., et al. J Clin Oncol. 18:2000;3339-3345
10. Vacha P., Fehlauer F., Mahlmann B., et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol. 179:2003;385-389
11. Lorusso D., Ferrandina G., Greggi S., et al., Multicenter Italian Trials in Ovarian Cancer Investigators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 14:2003;1086-1093
12. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 14:1996;2101-2112
13. Cui H., Zhang S., Li P., et al. Amifostine in protection of kidney from cisplatinum injury. [in Chinese] Zhonghua Zhong Liu Za Zhi. 24:2002;48-50
14. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 17:1999;3333-3355
15. Orditura M., De Vita F., Roscigno A., et al. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity. Oncol Rep. 6:1999;1357-1362
16. Komaki R., Lee J.S., Kaplan B., et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol. 12:(Suppl 1):2002;46-49
17. Aapro M., Extermann M., Repetto L. Evaluation of the elderly with cancer. Ann Oncol. 11:(Suppl 3):2000;223-229
18. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:1982;649-655
19. Tamhane A.C., Logan B.R. Accurate critical constants for the one-sided approximate likelihood ratio test of a normal mean vector when the covariance matrix is estimated. Biometrics. 58:2002;650-656
20. Bukowski R.M. Amifostine (Ethyol): Dosing, administration and patient management guidelines. Eur J Cancer. 32A:(Suppl 4):1996;S46-S49
21. Blumberg A.L., Nelson D.F., Gramkowski M., et al. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys. 8:1982;561-563
22. Viele C.S., Holmes B.C. Amifostine: Drug profile and nursing implications of the first pancytoprotectant. Oncol Nurs Forum. 25:1998;515-523
23. Koukourakis M.I. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs. 13:2002;181-209
24. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf. 24:2001;19-38
25. Dorr R.T., Holmes B.C. Dosing considerations with amifostine: A review of the literature and clinical experience. Semin Oncol. 26:(Suppl 7):1999;108-119
26. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. published correction appears in Semin Oncol. 30:2003;417
27. Anne P.R. Semin Oncol. 29:(Suppl 19):2002;80-83
28. Bardet E., Martin L., Calais G., et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 29:(Suppl 19):2002;57-60
29. Ryan S.V., Carrithers S.L., Parkinson S.J., et al. Hypotensive mechanisms of amifostine. J Clin Pharmacol. 36:1996;365-373
30. Gridelli C., Cigolari S., Maiorino A., et al. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: A multicenter phase II study. Lung Cancer. 28:2000;237-244